Stock Taper 
| DATE | TYPE | RATIO |
|---|---|---|
| 2024-09-11 | Reverse | 1:30 |
| 2024-04-09 | Reverse | 1:20 |
| 2023-06-29 | Reverse | 1:40 |
| 2023-03-27 | Reverse | 1:35 |
Allarity Therapeutics, Inc. is a Cambridge-based clinical-stage biopharma developing oncology drugs like Stenoparib and Dovitinib, utilizing drug-specific diagnostics and advancing multiple candidates in Phase 2 trials.
Stenoparib, an oral dual PARP and WNT inhibitor by Allarity Therapeutics, is in Phase 2 trials for ovarian and lung cancers, with FDA Fast Track designation for advanced ovarian cancer.
In August 2025, the U.S. Food and Drug Administration (FDA) granted Fast Track designation to Allarity Therapeutics' lead drug candidate, stenoparib, for the treatment of advanced ovarian cancer. This designation is intended to expedite the development and review of drugs for serious conditions with unmet medical needs and was a significant validation of stenoparib's potential. The news was a major catalyst for the company, leading to a substantial increase in its stock price and drawing considerable attention from investors and analysts.
In 2025, Allarity Therapeutics made the strategic decision to expand the clinical development of its sole lead asset, stenoparib, into a second indication: recurrent Small Cell Lung Cancer (SCLC). This move diversifies the company's clinical pipeline beyond its primary focus on ovarian cancer and targets a disease with high unmet medical needs.
Evogene (NASDAQ: EVGN - Get Free Report) and Allarity Therapeutics (NASDAQ: ALLR - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, profitability, earnings, dividends, analyst recommendations, valuation and institutional ownership. Institutional and Insider Ownership 10.4% of Evogene shares
Allarity Therapeutics (NASDAQ: ALLR - Get Free Report) and Autolus Therapeutics (NASDAQ: AUTL - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, dividends, valuation and earnings. Analyst Recommendations This is a breakdown of
- Recently awarded patents have solidified Allarity's strategy to leverage DRP to ensure the commercial exclusivity of stenoparib TARPON SPRINGS, Fla., September 30, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor— today provided an update on recent advances in its proprietary Drug Response Predictor (DRP®) technology, patent portfolio and in-house laboratory capabilities that strengthen its ability to drive stenoparib's clinical development while expanding external partnership opportunities.
Overall rating: C-
| PEER | PRICE | |
|---|---|---|
 CING | $4.72 | COMPARE |
 BCTX | $4.14 | COMPARE |
 LEXX | $2.94 | COMPARE |
 PCSA | $1.50 | COMPARE |
 CRIS | $0.76 | COMPARE |
